- Home
- EXK vs TNGX Comparison
EXK vs TNGX Comparison
Compare EXK & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXK | TNGX |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EXK | TNGX |
|---|---|---|
| Price | $9.33 | $19.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $13.94 | ★ $21.78 |
| AVG Volume (30 Days) | ★ 7.7M | 2.6M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $69.59 | N/A |
| Revenue Next Year | $17.61 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $3.50 | $1.93 |
| 52 Week High | $15.15 | $28.41 |
Technical Indicators
Market Signals| Indicator | EXK | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 39.92 |
| Support Level | $8.47 | $7.08 |
| Resistance Level | $10.40 | $22.01 |
| Average True Range (ATR) | 0.63 | 1.71 |
| MACD | -0.09 | -0.49 |
| Stochastic Oscillator | 16.39 | 4.88 |
Price Performance
Historical ComparisonAbout EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.